SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
CAMBRIDGE, Mass.--(BUSINESS WIRE)--SciFluor Life Sciences, Inc., a private, clinical stage company, today announced that the European Patent Office has issued a patent (EP 2953948) for SF0166, a novel potent and selective small molecule inhibitor of integrin αvβ3, in retinal diseases. This patent is supported by an additional 5 patents issued earlier by the U.S. Patent and Trademark Office (US 9,266,884, US 9,518,053, US 9,593,114, US 9,717,729, and US 9,802,933) which provide intellectual prop